heat shock protein family D (Hsp60) member 1 pseudogene 6Genealiases: HSPD1-6P · HSPDP6
Q-omics provides the consensus-scored HSPD1P6 profile across patient tissues and cancer cell-line models. HSPD1P6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, HSPD1P6 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, HSPD1P6 RNA expression shows 15,304 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, COAD, and ACC as cancer lineages where HSPD1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPD1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPD1P6 survival associations across molecular data types. HSPD1P6 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPD1P6 RNA expression–survival associations across cancer types. High HSPD1P6 expression shows unfavorable associations in STAD, KIRP, ACC, LIHC, UVM and BRCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for HSPD1P6 RNA expression.
This table summarizes HSPD1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSPD1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPD1P6 shows higher tumor expression in COAD, KIRC, HNSC, LIHC, STAD and BRCA. The COAD box plot shows higher HSPD1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.471, t-test p < 0.001).
This table shows molecular features associated with HSPD1P6 in patient tissues and cancer cell lines. In patient samples, HSPD1P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
